Galectin Therapeutics Inc. (GALT)

[Tekterra]

I am in agreement after digging more and more into GALT. It would seems their best bet is the CX trail reporting end of the year.

I think if they prove it can at least stop the condition from worsening further, that's still worth it and not necessarily have to be able to reverse the condition. It would be valuable as combo therapy with other drugs from other companies.

I am holding a small position just in case something wild happens, but I don't invest heavy based on hype or speculations.

I also think CNAT has a better shot with Novartis, they start the new trail on time, and Novartis choose to take the deal then it's just meeting the milestones going forward, not to say CNAT won't have unexpected problems, but at least they are moving along with a big player and, no funding issue going forward.